ANI Pharmaceuticals posts record Q2 revenue of $211.4 million and raises 2025 guidance
ANI Pharmaceuticals reported second-quarter 2025 net revenues of $211.4 million, up 53.1% from a year earlier, and GAAP net income available to common shareholders of $8.1 million, or $0.36 per diluted share, compared with a loss of $0.14 per share in the prior-year period. The company raised its full-year 2025 guidance for net revenues to $818 million to $843 million and adjusted non-GAAP diluted EPS to $6.98 to $7.35.
Key points
- Q2 2025 net revenues were $211.4 million, up 53.1% year over year, or 37.0% on an organic basis excluding the Alimera acquisition.
- Cortrophin Gel net revenues were $81.6 million, up 66.0% year over year.
- GAAP diluted EPS was $0.36 versus a loss of $0.14 a year earlier; adjusted non-GAAP diluted EPS was $1.80 versus $1.02.
- Full-year 2025 net revenue guidance was raised to $818 million to $843 million from $768 million to $793 million.
The filing
Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 08, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.